GleamWall
中文EN

MGTX MeiraGTx Holdings plc

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1735438 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,365.9%
TTM net income YoY146.4%
TTM EPS YoY141.2%
Revenue 3-yr CAGR291.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin44.8%
Net margin19.5%
FCF margin-0.7%
EBITDA margin47.8%

Returns

ROE89.7%
ROA26.0%
ROIC (approx.)—
Asset turnover1.34x

Leverage & solvency

Liabilities / assets47.7%
Debt / equity0.00x
Current ratio4.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.02x
Accruals ratio25.6%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$81.39M$33.28M
R&D expense$129.62M$119.48M
SG&A expense$52.90M$54.22M
Operating income-$105.97M-$164.21M
Interest expense$12.20M$13.27M
Pretax income-$114.20M-$147.79M
Income tax$0$0
Net income-$114.20M-$147.79M
EBITDA-$93.43M-$151.38M
EPS (basic)-1.42-2.12
EPS (diluted)-1.42-2.12
Weighted avg. shares (diluted)80.43M69.82M
Balance sheet
Cash & equivalents$65.93M$105.67M
Receivables$3.00M$707,000
Inventory—$385,000
Current assets$91.76M$123.52M
PP&E, net$105.47M$102.88M
Intangibles$578,000$821,000
Total assets$244.43M$269.75M
Current liabilities$122.56M$60.78M
Total liabilities$250.22M$201.92M
Shareholders' equity-$5.79M$67.83M
Shares outstanding81.12M78.40M
Cash flow statement
Operating cash flow-$46.36M-$104.50M
Capital expenditure$3.83M$4.96M
Free cash flow-$50.19M-$109.45M
Investing cash flow-$4.11M$23.48M
Financing cash flow$12.27M$54.53M
Depreciation & amortization$12.54M$12.83M
Stock-based compensation$22.11M$25.19M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.